Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor, Metabolic, and Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IGF1R drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IGF1R ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). Theoretical MW confirmed. |
View IGF1R Products |
| Gene Delivery | IGF1R Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Preserves native conformation for internalization assays. |
View IGF1R Products |
| Benchmark Ab | Anti-IGF1R (Reference Biosimilar Sequences, e.g., Teprotumumab, Figitumumab) Recombinant positive control for binding assays and assay standardization. |
View IGF1R Products |
| Validator | IGF1R siRNA Set For knockdown verification and specificity controls. |
View IGF1R Products |
| Related Target A | INSR High homology off-target counter-screening (ECD & Kinase domain panels). Critical for selectivity and toxicity avoidance. |
View INSR Products |
| Related Target B | IGF1 Primary natural ligand for competitive binding and functional agonist/antagonist assays. |
View IGF1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| INSR Homology Counter-Screening | Human IGF1R and INSR ortholog proteins available with >95% purity; Sequence Verified by Mass Spec. |
| Cross-species Cyno/Mouse Evaluation | Human/Mouse/Cyno IGF1R ECD-Fc orthologs with Endotoxin <1 EU/µg for preclinical safety assessment. |
| ADC Internalization & Conformation | HEK293-expressed ECD-Fc maintains native disulfide bond pattern; Suitable for fluorescence-based internalization assays. Lentivirus premade particles for stable target cell line construction. |
| Lack of Positive Controls | Clinical Benchmark Antibody sequences (biosimilar scaffolds) included for assay standardization. |
| Off-target Specificity Checks | Validated siRNA included for target knockdown confirmation in cell-based assays. |
Live IGF1R R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IGF1R therapeutics is intensifying, with major players shifting focus from first-generation monoclonal antibodies to next-generation ADCs, bispecific formats, and targeted degradation strategies. Following the commercial success of Teprotumumab (Tepezza) for Thyroid Eye Disease (TED), the field is expanding beyond oncology into autoimmune indications. As the field addresses historical challenges with metabolic on-target toxicity—primarily driven by cross-reactivity with the Insulin Receptor (INSR)—the next wave of R&D is targeting epitope-engineered biologics and ligand-displacement modalities designed to spare INSR while maximizing tumor-specific payload delivery. Key areas include highly potent ADCs for solid tumors (Ewing sarcoma, HR+ breast cancer) and bispecific formats (IGF1R x EGFR/HER2) to bypass acquired resistance mechanisms.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Emerging Biotech & Pharma Partners (e.g., Carmot Therapeutics, Innovent Biologics) | Solid Tumors (Sarcoma, Breast, Lung, HCC) | Internalization Assay (Need high-purity ECD-Fc with native glycosylation; Lentivirus for cell lines) |
| Bispecific | IGF1R x EGFR / IGF1R x HER2 Developers (e.g., Merck, AstraZeneca) | Solid Tumors, Refractory Carcinomas | Heterodimer Validation & Cross-reactive Binding (Need conformationally intact antigen panels) |
| Small Molecule TKI | Specialty Oncology Pharma (e.g., Astellas, Boehringer Ingelheim, OSI Pharmaceuticals) | Refractory Solid Tumors, Neuroblastoma | Selectivity Assay (Need IGF1R vs INSR Kinase Domain mutant and WT proteins) |
| mAb / Fusion Protein | Legacy & Next-Gen Developers (e.g., Horizon/Amgen, Pierre Fabre) | Thyroid Eye Disease (TED), Ewing Sarcoma, NSCLC | Ligand-Competition SPR (Need ECD-Fc with native IGF1/IGF2 binding kinetics); INSR Selectivity Assay |
Key Functional Domains & Mutations
IGF1R (UniProt P08069) contains three Fibronectin type-III domains (1, 2, 3) critical for ligand binding and receptor dimerization. Key mutations include:
- Somatic mutation in renal chromophobe sample (VAR_041424)
- Decreased IGF1R function mutations in IGF1RES: rs121912426 (VAR_034891) and rs121912427 (VAR_034892)
These mutations are relevant for understanding resistance mechanisms and designing selective therapeutics.